作者
Myong Cheol Lim, Suk-Joon Chang, Boram Park, Heon Jong Yoo, Chong Woo Yoo, Byung Ho Nam, Sang-Yoon Park, Sang-Soo Seo, Sokbom Kang, Jung Yeon Yun, Dae-Soon Cho, Sun Ho Kim, Tae-Sung Kim, Sung Sil Park, Dong Woon Lee, Sung Chan Park, Hyeong Min Park, Sung-Sik Han, Seoung Hoon Kim, Hee Chul Yang, Moon Soo Kim, Jong Mog Lee, Bang Wool Eom, Young Il Kim, Hong Man Yoon, Il Ju Choi, Sung Han Kim, Jae Young Joung, Ho Kyung Seo, Jung Nam Joo, Yong Jung Song, Sae Hyun Park, Dae Chul Jung, Min Jung Kim, Ji Won Park, Seung-Yong Jeong, Young Ho Yun, Sohee Park, Robert E Bristow, HIPEC for Ovarian Cancer Collaborators
发表日期
2022/5/1
期刊
JAMA surgery
卷号
157
期号
5
页码范围
374-383
出版商
American Medical Association
简介
Importance
Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery.
Objective
To assess the clinical benefit of HIPEC after primary or interval maximal cytoreductive surgery in women with stage III or IV primary advanced ovarian cancer.
Design, Setting, and Participants
In this single-blind randomized clinical trial performed at 2 institutions in South Korea from March 2, 2010, to January 22, 2016, a total of 184 patients with stage III or IV ovarian cancer with residual tumor size less than 1 cm were randomized (1:1) to a HIPEC (41.5 °C, 75 mg/m2of cisplatin, 90 minutes) or control group. The primary end point was progression-free survival. Overall survival and adverse events were key secondary end points. The …
学术搜索中的文章
MC Lim, SJ Chang, B Park, HJ Yoo, CW Yoo, BH Nam… - JAMA surgery, 2022